Capital Market Strategies LLC Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital Market Strategies LLC bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 11,715 shares of the company's stock, valued at approximately $461,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Larson Financial Group LLC boosted its position in shares of CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company's stock valued at $31,000 after acquiring an additional 276 shares during the period. Itau Unibanco Holding S.A. bought a new position in shares of CRISPR Therapeutics in the second quarter worth $35,000. Wilmington Savings Fund Society FSB bought a new position in CRISPR Therapeutics in the 3rd quarter valued at about $40,000. Darwin Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics in the 3rd quarter valued at approximately $43,000. Finally, National Bank of Canada FI lifted its holdings in shares of CRISPR Therapeutics by 35.0% during the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company's stock worth $46,000 after acquiring an additional 220 shares during the period. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Stock Up 3.4 %

CRSP traded up $1.41 during midday trading on Monday, hitting $42.43. The company had a trading volume of 2,425,167 shares, compared to its average volume of 1,844,358. The company has a market capitalization of $3.62 billion, a price-to-earnings ratio of -14.99 and a beta of 1.68. The stock's 50 day moving average price is $46.77 and its 200 day moving average price is $49.04. CRISPR Therapeutics AG has a 52 week low of $38.20 and a 52 week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same quarter last year, the firm posted ($1.41) EPS. Research analysts predict that CRISPR Therapeutics AG will post -5.13 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CRSP. JMP Securities reiterated a "market outperform" rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Barclays decreased their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Wednesday, November 6th. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a report on Monday, December 30th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $53.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $77.93.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares of the company's stock, valued at approximately $10,484,271.20. The trade was a 1.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares of the company's stock, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,382 shares of company stock valued at $2,744,179 over the last ninety days. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.